HK1122988A1 - Proteasome inhibitors and uses thereof - Google Patents

Proteasome inhibitors and uses thereof

Info

Publication number
HK1122988A1
HK1122988A1 HK09100183.8A HK09100183A HK1122988A1 HK 1122988 A1 HK1122988 A1 HK 1122988A1 HK 09100183 A HK09100183 A HK 09100183A HK 1122988 A1 HK1122988 A1 HK 1122988A1
Authority
HK
Hong Kong
Prior art keywords
proteasome inhibitors
proteasome
inhibitors
Prior art date
Application number
HK09100183.8A
Other languages
English (en)
Inventor
Jack Arbiser
Original Assignee
Jack Arbiser
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jack Arbiser filed Critical Jack Arbiser
Publication of HK1122988A1 publication Critical patent/HK1122988A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Plant Substances (AREA)
HK09100183.8A 2005-05-20 2009-01-08 Proteasome inhibitors and uses thereof HK1122988A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68338505P 2005-05-20 2005-05-20
PCT/US2006/019591 WO2006127525A2 (fr) 2005-05-20 2006-05-19 Inhibiteurs de proteasome et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
HK1122988A1 true HK1122988A1 (en) 2009-06-05

Family

ID=37452658

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09100183.8A HK1122988A1 (en) 2005-05-20 2009-01-08 Proteasome inhibitors and uses thereof

Country Status (10)

Country Link
US (1) US8809283B2 (fr)
EP (2) EP1895971A4 (fr)
JP (2) JP5745743B2 (fr)
CN (1) CN101222900B (fr)
AU (1) AU2006251655B2 (fr)
CA (1) CA2609213C (fr)
ES (1) ES2891179T3 (fr)
HK (1) HK1122988A1 (fr)
IL (1) IL187463A (fr)
WO (1) WO2006127525A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110118274A1 (en) * 2007-08-23 2011-05-19 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
FR2926955B1 (fr) 2008-02-01 2012-07-20 Agronomique Inst Nat Rech Procede de preparation d'acides dicafeoylquiniques et leur utilisation dans la lutte contre les pucerons
WO2013025986A2 (fr) 2011-08-17 2013-02-21 Basf Corporation Principes actifs cosmétiques d'origine marine et leur utilisation
WO2013163512A1 (fr) 2012-04-26 2013-10-31 The General Hospital Corporation Agents et méthodes de traitement et de prévention des verrues séborrhéiques
CN109096370B (zh) * 2012-07-26 2022-03-18 圣特莱国际公司 多肽环氧酮化合物
WO2014175518A1 (fr) * 2013-04-23 2014-10-30 한국식품연구원 Composition pour soulager, prévenir ou traiter la douleur contenant de l'extrait de maté comme principe actif et procédé pour évaluer l'efficacité du soulagement, de la prévention ou du traitement de la douleur d'un échantillon
KR101483990B1 (ko) 2013-04-23 2015-01-20 한국식품연구원 시료의 통증 완화, 예방 또는 치료 효능에 대한 평가방법
WO2014186663A2 (fr) 2013-05-17 2014-11-20 The General Hospital Corporation Procédés de détection et de traitement de variantes de kératoses séborrhéiques
GB201317286D0 (en) 2013-09-30 2013-11-13 Calscience Internat Ltd Composition and Use
CN104546819A (zh) * 2013-10-09 2015-04-29 中国医学科学院药物研究所 二咖啡酰奎宁酸在治疗系统性自身免疫性疾病中的用途
WO2015103012A1 (fr) * 2013-12-31 2015-07-09 Applied Biology, Inc. Procédés et compositions pour l'administration d'une photothérapie à longueur d'onde spécifique
GB201502268D0 (en) 2015-02-11 2015-04-01 Calscience Internat Ltd Dental composition and use
CA3004587A1 (fr) * 2015-11-06 2017-05-11 Accuitis Pharmaceuticals, Inc. Utilisation d'inhibiteurs du proteasome afin de traiter de troubles oculaires
BR112019015721A2 (pt) 2017-01-30 2020-03-24 Western New England University Inibidores de tiol isomerases e uso dos mesmos
WO2019089942A1 (fr) * 2017-11-02 2019-05-09 Rick Coulon Formulations destinées à être utilisées dans l'administration transdermique d'inhibiteurs du protéasome
FR3080032B1 (fr) * 2018-04-13 2020-04-17 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Utilisation d'une nouvelle composition pour empecher ou ralentir l'apparition de signes d'inflammation
FR3080030B1 (fr) * 2018-04-13 2020-04-24 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Utilisation d’une nouvelle composition pour empecher ou ralentir l’apparition des signes inesthetiques lies a la presence de sebum en exces

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034412A (en) * 1987-03-17 1991-07-23 Merrell Dow Pharmacueticals Inc. Method of inhibiting interleukin-1 release
JPH05501860A (ja) * 1989-07-14 1993-04-08 バイオドール―ユー．エス．ホールディング　コーポレーション 新規の抗ウィルス剤
US6355684B1 (en) 1990-10-11 2002-03-12 Meryl J. Squires Antimicrobial treatment for herpes simplex virus and other infectious diseases
EP0582147A3 (en) * 1992-08-03 1994-08-24 Nestle Sa Anti-urease cosmetic or dermatologic composition
WO1994026282A1 (fr) * 1993-05-17 1994-11-24 Omega Pharmaceuticals, Inc. Procede de traitement de pathologies
US5811101A (en) * 1997-04-29 1998-09-22 Waltman Pharmaceuticals Incorporated Composition for treating acne
DE59900888D1 (de) * 1998-01-26 2002-04-04 Ciba Sc Holding Ag Molekulargewichtserhöhung und Stabilisierung von Polykondensaten mit Diepoxiden von sterisch gehinderten Aminen
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
US6632459B2 (en) 2000-12-11 2003-10-14 Nutricia N.V. Chlorogenic acid and an analog thereof for immune system stimulation
US7381427B2 (en) * 2001-02-09 2008-06-03 Mickey Miller Seborrheic keratosis treatment
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
US8728445B2 (en) 2001-05-01 2014-05-20 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences Hydrogel Compositions
US6464025B1 (en) * 2001-05-15 2002-10-15 Crown Equipment Corporation Coast control for walkie/rider pallet truck
EP1260212A1 (fr) * 2001-05-21 2002-11-27 Cognis France S.A. Composition cosmetique
WO2003000634A1 (fr) * 2001-06-20 2003-01-03 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Antagonistes des recepteurs de la vitamine d et compositions et methodes d'utilisation associees
US20030105031A1 (en) 2001-11-06 2003-06-05 Rosenbloom Richard A. Methods for the treatment of skin disorders
US7217853B2 (en) * 2002-05-24 2007-05-15 Corium International, Inc. Composition for cushions, wound dressings and other skin-contacting products
US20040156873A1 (en) * 2003-02-10 2004-08-12 Gupta Shyam K. Topically Bioavailable Acne and Rosacea Treatment Compositions
WO2004103432A2 (fr) * 2003-05-20 2004-12-02 Avery Dennison Corporation Masques faciaux pour traiter des plaies cutanees
US20050014637A1 (en) * 2003-06-04 2005-01-20 Duijghuisen Henricus Petrus Bernardus Polyether polyol composition
DE10336883A1 (de) * 2003-08-08 2005-03-10 Basf Ag Kunststoff, insbesondere Polyurethan enthaltend ein sterisch gehindertes, verestertes Amin
DE602004008095T2 (de) * 2003-10-07 2008-04-30 Dow Global Technologies, Inc., Midland Polypropylenzusammensetzung für luftgekühlte blasfolien
US8057785B2 (en) * 2004-12-22 2011-11-15 Omj Ireland Limited Phototherapy compositions and methods
WO2006066987A1 (fr) * 2004-12-22 2006-06-29 Ciba Specialty Chemicals Holding Inc. Agents antiradicaux

Also Published As

Publication number Publication date
EP1895971A2 (fr) 2008-03-12
US20070004647A1 (en) 2007-01-04
EP3087969B1 (fr) 2021-06-30
WO2006127525A3 (fr) 2007-03-15
CA2609213C (fr) 2016-08-23
CN101222900A (zh) 2008-07-16
IL187463A0 (en) 2008-03-20
IL187463A (en) 2015-08-31
ES2891179T3 (es) 2022-01-26
WO2006127525A2 (fr) 2006-11-30
EP1895971A4 (fr) 2012-08-08
US8809283B2 (en) 2014-08-19
JP2008540682A (ja) 2008-11-20
JP2013177463A (ja) 2013-09-09
JP5745743B2 (ja) 2015-07-08
AU2006251655A1 (en) 2006-11-30
CA2609213A1 (fr) 2006-11-30
AU2006251655B2 (en) 2012-10-11
EP3087969A1 (fr) 2016-11-02
CN101222900B (zh) 2013-02-13

Similar Documents

Publication Publication Date Title
IL187463A0 (en) Proteasome inhibitors and uses thereof
IL228770A0 (en) processes and intermediates
EP1742627A4 (fr) Inhibiteurs de pde4b et leurs utulisations
EP1812049A4 (fr) Inhibiteurs de kallikreine et leurs utilisations
EP1920216A4 (fr) Signalisation et orientation d'emplacement
IL179398A0 (en) Dpp-ib inhibitors
ZA200810323B (en) Fkbp-l and uses thereof
IL192134A0 (en) Soft protease inhibitors and pro-soft forms thereof
SI2064327T1 (sl) DBAIT in njegova uporaba
IL179497A0 (en) Carboranylporphyrins and uses thereof
ZA200804299B (en) 3-amino-2-arylpropyl azaindoles and uses thereof
HK1133552A1 (en) Carboranylporphyrins and uses thereof
IL189252A0 (en) Dihydroxyanthraquinones and their use
EP1921066A4 (fr) Composé de pyridylphénol et son utilisation
IL185223A0 (en) Compounds and uses thereof
IL181819A0 (en) Enzyme inhibitors and uses thereof
IL180365A0 (en) Carboranylporphyrins and uses thereof
GB0421355D0 (en) Inhibitors
GB0520935D0 (en) Integrated processor-template-system and project
GB0421356D0 (en) Inhibitors
GB0516967D0 (en) Inhibitors
GB0505620D0 (en) Methods and materials therefor
GB0517240D0 (en) Chronorotron mk1-system and project
GB0517239D0 (en) Geogrotren-mk1-system and project
GB0522259D0 (en) e-s-spi-l-d-film-cinema-back-engineering armageddon-system and project